Nova Southeastern University Office of Academic Affairs Search NSU Site Map Nova Southeastern University
President's Faculty R & D Grant 
Committees, Councils
  and Boards
Faculty Policy Manual
NSU Scholarly Journals
Professional Journals
Prof. Memberships
Academic Policies & Procedures
Provost's Research and Scholarship Award
President's Faculty
 R & D Grant
PFRDG Application Review Process by NSU Librarians
Office of Academic Quality, Assessment, and Accreditation
Contact Us

Print this page  


With a focus on learning, we employ a range of strategies to support innovation, collaboration across centers, and university-wide discussion and decision-making


Seventh Annual Grant Winners 2006-2007

Gary M. Levin, Pharm.D. – HPD College of Pharmacy
Sarah Popish, Pharm.D. – HPD College of Pharmacy
Naushira Pandya, M.D. – HPD College of Osteopathic Medicine

Andres Malave, Dean, - HPD College of Pharmacy
Anthony Silvagni, Dean, - HPD College of Osteopathic Medicine

Title: Assessment of a Butyrylcholinesterase Variant in Alzheimer’s Patients


The gold standard of treatment for Alzheimer’s disease is the acetylcholinesterase (AChE) inhibitors.  There are currently four AChE inhibitors available: tacrine, rivastigmine, galantamine, and donepezil.  Donepezil and galantamine are AChE-selective, while tacrine and rivastigmine are dual inhibitors of both AChE and butyrylcholinesterase (BuChE).

The common BuChE variants, are the BuChE-K variant and the atypical variant.  Patients with these substitutions will potentially have a higher level of acetylcholine in their brains, and they would be expected to have better attentional performance than those individuals with the wild type (normal) BuChE.  Further reduction of the enzyme from the medication may not have an additional impact upon their acetylcholine levels.

This study will try to determine the allelic frequency of the BuChE-K variant in a control population versus a population of Alzheimer’s patients among five different ethnic groups prevalent in south Florida.